Convalescent Plasma and Hyperimmune Globulin Therapy in COVID-19.

Cagdas D. N.

Expert review of clinical immunology, vol.17, pp.309-315, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2021
  • Doi Number: 10.1080/1744666x.2021.1894927
  • Journal Name: Expert review of clinical immunology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.309-315
  • Keywords: Convalescent Plasma, hyperimmune globulin, efficacy, adverse effects, application, use, SARS-CoV-2, COVID-19, antibody, autoantibody, ANTIBODY-DEPENDENT ENHANCEMENT, ACUTE RESPIRATORY SYNDROME, SYNDROME CORONAVIRUS 2
  • Hacettepe University Affiliated: Yes


Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. As convalescent plasma (CP) therapy has been used with success in several viral infections before, it has become a treatment of choice. Medical literature is reviewed for randomized controlled studies using convalescent plasma therapy.